High c-Myb Expression Associates with Good Prognosis in
Colorectal Carcinoma

J 2019

High c-Myb Expression Associates with Good Prognosis in Colorectal Carcinoma

TICHÝ, Michal, Lucia KNOPFOVÁ, Jiří JARKOVSKÝ, Petr VLČEK, Jana KATOLICKÁ et. al.

Základní údaje

Originální název

High c-Myb Expression Associates with Good Prognosis in Colorectal Carcinoma

Autoři

TICHÝ, Michal (203 Česká republika, domácí), Lucia KNOPFOVÁ (203 Česká republika, domácí), Jiří JARKOVSKÝ (203 Česká republika, domácí), Petr VLČEK (203 Česká republika), Jana KATOLICKÁ (203 Česká republika), Ivan ČAPOV (203 Česká republika), Markéta HERMANOVÁ (203 Česká republika, domácí), Jan ŠMARDA (203 Česká republika, domácí) a Petr BENEŠ (203 Česká republika, garant, domácí)

Vydání

Journal of Cancer, Australia, IVYSPRING INT PUBL, 2019, 1837-9664

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Austrálie

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.565

Kód RIV

RIV/00216224:14310/19:00107306

Organizační jednotka

Přírodovědecká fakulta

DOI

http://dx.doi.org/10.7150/jca.29530

UT WoS

000459711200007

Klíčová slova anglicky

c-Myb; colorectal cancer; prognosis; survival

Štítky

14110112, 14119612, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 16. 3. 2020 16:32, Mgr. Marie Šípková, DiS.

Anotace

V originále

Colorectal cancer (CRC) represents a serious challenge for oncologists due to high incidence and large heterogeneity. Prognostic factors are needed to stratify patients according to risk of disease progression. In this study, we report that high expression of c-Myb protein, determined by immunohistochemistry (IHC), associates with better overall and disease-free survival (OS, DFS) in a cohort of 103 patients. Although MYB has been previously considered to act as oncogene in CRC, our further analysis of datasets deposited in PrognoScan and SurvExpress databases confirmed that high MYB expression largely associates with good prognosis in CRC. As therapies targeting c-Myb have been developed and tested in preclinical studies, we believe that further studies are needed for detailed understanding of c-Myb function in CRC, before the c-Myb-targeted therapy enters clinical trials.

Návaznosti

GJ17-08985Y, projekt VaV

Název: Prozánětlivá signalizace pod kontrolou proteinu c-Myb v bazálních prsních karcinomech

Investor: Grantová agentura ČR, c-Myb-regulated inflammatory circuit in basal-like mammary tumors

NV18-07-00073, projekt VaV

Název: c-Myb a jeho transkripční program ve fyziologických a patologických osteogenních procesech

Investor: Ministerstvo zdravotnictví ČR, c-Myb a jeho transkripční program ve fyziologických a patologických osteogenních procesech

Citovat

TICHÝ, Michal, Lucia KNOPFOVÁ, Jiří JARKOVSKÝ, Petr VLČEK, Jana KATOLICKÁ, Ivan ČAPOV, Markéta HERMANOVÁ, Jan ŠMARDA a Petr BENEŠ. High c-Myb Expression Associates with Good Prognosis in Colorectal Carcinoma. Journal of Cancer. Australia: IVYSPRING INT PUBL, 2019, roč. 10, č. 6, s. 1393-1397. ISSN 1837-9664. Dostupné z: https://dx.doi.org/10.7150/jca.29530.

@article{1503876,
   author = {Tichý, Michal and Knopfová, Lucia and Jarkovský, Jiří and Vlček, Petr and Katolická, Jana and Čapov, Ivan and Hermanová, Markéta and Šmarda, Jan and Beneš, Petr},
   article_location = {Australia},
   article_number = {6},
   doi = {http://dx.doi.org/10.7150/jca.29530},
   keywords = {c-Myb; colorectal cancer; prognosis; survival},
   language = {eng},
   issn = {1837-9664},
   journal = {Journal of Cancer},
   title = {High c-Myb Expression Associates with Good Prognosis in Colorectal Carcinoma},
   url = {http://www.jcancer.org/v10p1393.htm},
   volume = {10},
   year = {2019}
}

TY  - JOUR
ID  - 1503876
AU  - Tichý, Michal - Knopfová, Lucia - Jarkovský, Jiří - Vlček, Petr - Katolická, Jana - Čapov, Ivan - Hermanová, Markéta - Šmarda, Jan - Beneš, Petr
PY  - 2019
TI  - High c-Myb Expression Associates with Good Prognosis in Colorectal Carcinoma
JF  - Journal of Cancer
VL  - 10
IS  - 6
SP  - 1393-1397
EP  - 1393-1397
PB  - IVYSPRING INT PUBL
SN  - 18379664
KW  - c-Myb
KW  - colorectal cancer
KW  - prognosis
KW  - survival
UR  - http://www.jcancer.org/v10p1393.htm
L2  - http://www.jcancer.org/v10p1393.htm
N2  - Colorectal cancer (CRC) represents a serious challenge for oncologists due to high incidence and large heterogeneity. Prognostic factors are needed to stratify patients according to risk of disease progression. In this study, we report that high expression of c-Myb protein, determined by immunohistochemistry (IHC), associates with better overall and disease-free survival (OS, DFS) in a cohort of 103 patients. Although MYB has been previously considered to act as oncogene in CRC, our further analysis of datasets deposited in PrognoScan and SurvExpress databases confirmed that high MYB expression largely associates with good prognosis in CRC. As therapies targeting c-Myb have been developed and tested in preclinical studies, we believe that further studies are needed for detailed understanding of c-Myb function in CRC, before the c-Myb-targeted therapy enters clinical trials.
ER  -

TICHÝ, Michal, Lucia KNOPFOVÁ, Jiří JARKOVSKÝ, Petr VLČEK, Jana KATOLICKÁ, Ivan ČAPOV, Markéta HERMANOVÁ, Jan ŠMARDA a Petr BENEŠ. High c-Myb Expression Associates with Good Prognosis in Colorectal Carcinoma. \textit{Journal of Cancer}. Australia: IVYSPRING INT PUBL, 2019, roč.~10, č.~6, s.~1393-1397. ISSN~1837-9664. Dostupné z: https://dx.doi.org/10.7150/jca.29530.

Podrobný výpis o publikaci